Better Health for All

STRATEC SE's core business involves designing and manufacturing fully automated analyzer systems for in-vitro diagnostics and life sciences, including system-related consumables.

These products are used in clinical diagnostics and drug discovery, indicating that the company's entire business is devoted to health improvement, delivering exceptional health benefits. There is no evidence of any products with negative health outcomes. In 2024, STRATEC SE allocated 21.5% of its sales to gross R&D expenses, demonstrating a significant investment in health innovation aimed at transforming major global health challenges.

Fair Money & Economic Opportunity

STRATEC SE is a medical technology company that designs and manufactures analyzer systems and consumables for in-vitro diagnostics and life sciences.

Its core business does not involve lending, deposit services, or other financial products for consumers. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives (financial), data accessibility (financial), fair lending compliance, wealth building outcomes, profit reinvestment (in community finance), financial literacy initiatives, debt burden ratio, geographic inclusion (financial access points), and product simplicity (financial products), are not applicable to the company's operations. No evidence was found in the provided articles to suggest the company engages in activities relevant to these financial services-focused KPIs.

Fair Pay & Worker Respect

In the 2024 financial year, the ratio of the highest paid individual's total annual remuneration to the median employee's total annual remuneration was 25.5.

As of December 31, 2024, 15.8% of company employees were covered by collective bargaining agreements. The rate of recordable work-related accidents was 7.6 in 2024, with 18 work-related accidents and no fatalities. The unadjusted gender pay gap was 27.4% in 2024. The voluntary employee turnover rate was 16.8% in 2024. The company reported zero incidents of discrimination, zero severe human rights violations, and zero fines or penalties for incidents and complaints in 2024. There were 21 complaints filed through internal channels in 2024. As of December 31, 2024, the company had 1,386 permanent employees, 28 temporary employees, and 1 non-guaranteed hours employee, out of a total of 1,414 employees.

Fair Trade & Ethical Sourcing

STRATEC SE reported zero human rights breaches identified in 2023 or prior years.

The company has a Code of Conduct for Business Partners and outlines due diligence processes in its sustainability strategy. No specific quantitative data was provided for fair trade certification, audit frequency, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend.

Honest & Fair Business

The company has an anonymous whistleblower system in place since 2017, accessible via its website, which allows anonymous reporting and offers protection from retaliation for potential or actual infringements, misconduct, human rights-related risks, and environmental breaches.

A Corporate Compliance Policy exists, along with a strong rejection of corruption in all forms, supported by training programs, specific guidance on gifts and benefits, and a money laundering prevention policy. However, there is no evidence regarding the frequency or effectiveness of anti-corruption training, nor details on the independence of whistleblower investigation processes. The company's quality management system is certified, and external audit opinions are mentioned, but the extent of independent verification for ethical claims beyond these is not specified.

Kind to Animals

The company develops hematology analyzers and reagents for veterinary use, capable of blood analysis for 13 different animal species.

However, no information is provided regarding the company's animal testing policy, the volume of animals used in testing, or any cruelty-free certifications for its products. There is also no data on the use of alternative testing methods, humane certifications for operations, or the percentage of animal-derived ingredients replaced with ethical alternatives. The company's core business model does not involve animal husbandry or captive operations, nor does it source eggs, meat, or dairy. While the company mentions supporting conservation organizations through donations, no specific measurable biodiversity impact or details of these organizations are provided. There is no evidence of participation in multi-stakeholder initiatives for animal-free standards or active engagement in animal welfare policy improvement.

No War, No Weapons

The company reported no donations to political parties or lobbyists in 2023 and 2022.

No other specific, quantifiable evidence related to the 'No War, No Weapons' value was found in the provided articles.

Planet-Friendly Business

In 2024, the company's total Scope 1, 2, and 3 greenhouse gas emissions were 51,082.8 tCO₂e.

This represents a significant increase from 10,227 tCO₂e in 2023. Its science-based targets, validated by SBTi in February 2025, include a 50.4% reduction in Scope 1, 2, and 3 emissions by 2032 from a 2023 base year, and a 90% reduction in all scopes by 2045, adapted to a 1.5°C pathway. The company aims for net-zero emissions by 2045. In 2024, 6,238.5 MWh of energy consumed was from renewable sources, representing 55.17% of its total energy consumption of 11,308.4 MWh. The company offset 1,800 tCO₂e in 2024, with 72.2% from Verra projects and 27.8% from Gold Standard projects. In 2024, 42.6% of its capital expenditure was aligned with the EU Taxonomy. The company reported zero environmental compliance violations in 2024. Climate scenario analysis has been performed, considering 1.5°C, 2°C, and 3°C+ pathways. An analysis of biodiversity at its locations identified no increased risks and deemed no remedial actions necessary.

Respect for Cultures & Communities

The company has no formal partnerships with indigenous or local community groups, which is consistent with its business model.

No cultural appropriation incidents have been reported. There is no specific cultural impact assessment protocol, which is also deemed not applicable given the nature of the company's operations. An anonymous whistleblower system has been in place since 2017, enabling employees or other parties to report breaches, which aligns with standard grievance processes. Free, Prior and Informed Consent (FPIC) processes are not applicable to the company's operations. There is no specific community representation on governance or advisory bodies. No cultural site disruptions have occurred, as the company does not operate near such sites. The concept of social license to operate is not applicable to the business model, and no cultural incidents have been reported, thus no specific response framework is detailed.